ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Dose Optimization of Piperacillin for Pseudomonas aeruginosa Infection in Febrile Neutropenic Pediatric Patients.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundFebrile neutropenic pediatric oncology patients require aggressive antimicrobial therapy against Pseudomonas aeruginosa, but standard piperacillin dosing may provide suboptimal exposure due to altered pharmacokinetics in this population.
objectiveThis simulation-based study aimed to evaluate the impact of loading doses, maintenance dose timing, and infusion duration on piperacillin pharmacodynamic target attainment in pediatric febrile neutropenia.
methodsMonte Carlo simulations were performed using a published population pharmacokinetic model. A virtual cohort of 5000 children across five weight groups (8-52 kg) was generated. Probability of target attainment (PTA) was assessed for two stringent pharmacodynamic targets: 50% fT > 4 × MIC and 100% fT > MIC against Pseudomonas aeruginosa at the EUCAST breakpoint MIC of 16 mg/L. Simulated regimens varied by loading dose, infusion duration, and timing of maintenance dose administration.
resultsStandard intermittent dosing (75-100 mg/kg every 6 h) failed to achieve adequate PTA for either target, even with loading doses up to 200 mg/kg. Accelerated maintenance dosing (3 h post-loading dose) with extended infusions achieved optimal PTA (> 90%) for the 50% fT > 4 × MIC target in patients ≥ 22 kg using loading doses of 100-150 mg/kg followed by 100 mg/kg every 6 h over 3 h. For the 100% fT > MIC target, only continuous infusion (300 mg/kg/day) with appropriate loading doses achieved 100% PTA across all weights.
conclusionConventional piperacillin dosing is insufficient in pediatric patients with febrile neutropenia. Loading dose with accelerated maintenance dosing achieves 50% fT > 4 × MIC, while continuous infusion is essential for 100% fT > MIC target attainment.
Indexed as
Identifiers
41483095What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.